Oral Lenacapavir (LEN)

DRUG2 trials

Sponsors

Gilead Sciences

Conditions

Pre-Exposure Prophylaxis of HIV Infection

Phase 3

Study of Lenacapavir for HIV Pre-Exposure Prophylaxis in People Who Are at Risk for HIV Infection

Active, not recruitingNCT04925752

Gilead SciencesPre-Exposure Prophylaxis of HIV Infection

Start: 2021-06-28End: 2028-08-31Updated: 2025-12-23

Pre-Exposure Prophylaxis Study of Lenacapavir and Emtricitabine/Tenofovir Alafenamide in Adolescent Girls and Young Women at Risk of HIV Infection

Active, not recruitingNCT04994509

Gilead SciencesPre-Exposure Prophylaxis of HIV Infection

Start: 2021-08-30End: 2028-01-01Updated: 2026-03-30

Related Papers

P-299. No Clinically Significant Drug-Drug Interactions Between Lenacapavir and Hormonal Contraceptives in PURPOSE 1

Open Forum Infectious Diseases2026-01-01

392. Favorable Adherence and Safety of Twice-Yearly Subcutaneous Lenacapavir for PrEP Among PURPOSE 2 Participants Who Used Substances

Open Forum Infectious Diseases2026-01-01

P-305. No Clinically Significant Drug–Drug Interactions with Co-administration of Feminizing or Masculinizing Hormone Therapy and Twice-yearly Lenacapavir PrEP in Gender-Diverse Persons

Open Forum Infectious Diseases2026-01-01

Twice-Yearly Lenacapavir for HIV Prevention in Men and Gender-Diverse Persons

New England Journal of Medicine2024-11-27159 citations

Twice-Yearly Lenacapavir or Daily F/TAF for HIV Prevention in Cisgender Women

New England Journal of Medicine2024-07-24338 citations

2059. Estimated Background HIV Diagnosis Rates among People Who Could Benefit from Pre-Exposure Prophylaxis (PrEP) at the Metropolitan Statistical Area (MSA) level in the United States, 2012-2019

Open Forum Infectious Diseases2022-12-01

Proactive strategies to optimize engagement of Black, Hispanic/Latinx, transgender, and nonbinary individuals in a trial of a novel agent for HIV pre-exposure prophylaxis (PrEP)

PLoS ONE2022-06-0339 citations